Do analysts prefer TTRX or LTRN?

Turn Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 12.36%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Turn Therapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, TTRX or LTRN?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A Lantern Pharma N/A N/A -$17.12M -$1.45 N/A

Is TTRX or LTRN more profitable?

Turn Therapeutics' return on equity of 0.00% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A Lantern Pharma N/A -198.34% -129.08%

Do analysts rate LTRN or DTIL?

Precision BioSciences has a consensus price target of $32.25, indicating a potential upside of 294.25%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Precision BioSciences 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Do analysts rate CGEN or LTRN?

Compugen presently has a consensus price target of $5.00, suggesting a potential upside of 119.30%. Given Compugen's stronger consensus rating and higher probable upside, equities analysts clearly believe Compugen is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CGEN or LTRN more profitable?

Compugen has a net margin of 47.97% compared to Lantern Pharma's net margin of 0.00%. Compugen's return on equity of 47.72% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Compugen 47.97% 47.72% 27.51% Lantern Pharma N/A -198.34% -129.08%

Do analysts rate NKTX or LTRN?

Nkarta presently has a consensus target price of $10.75, suggesting a potential upside of 233.85%. Given Nkarta's stronger consensus rating and higher probable upside, equities analysts clearly believe Nkarta is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, NKTX or LTRN?

Lantern Pharma is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A Lantern Pharma N/A N/A -$17.12M -$1.45 N/A

Is NKTX or LTRN more profitable?

Nkarta's return on equity of -30.90% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Lantern Pharma N/A -198.34% -129.08%

Do analysts recommend LTRN or TNXP?

Tonix Pharmaceuticals has a consensus price target of $24.00, suggesting a potential upside of 94.49%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tonix Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00

Lantern Pharma (LTRN) Competitors

$3.97 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.89 -0.08 (-2.02%)

As of 07/2/2026 07:38 PM Eastern

Compare

LTRN vs. TTRX, DTIL, CGEN, NKTX, and TNXP

Should you buy Lantern Pharma stock or one of its competitors? MarketBeat compares Lantern Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lantern Pharma include Turn Therapeutics (TTRX), Precision BioSciences (DTIL), Compugen (CGEN), Nkarta (NKTX), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry.

How does Lantern Pharma compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Lantern Pharma (NASDAQ:LTRN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Turn Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Turn Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 12.36%. Given Turn Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Turn Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Turn Therapeutics had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Lantern Pharma. Turn Therapeutics' average media sentiment score of 0.46 beat Lantern Pharma's score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Turn Therapeutics	Neutral
Lantern Pharma	Neutral

Turn Therapeutics' return on equity of 0.00% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Lantern Pharma	N/A	-198.34%	-129.08%

28.6% of Lantern Pharma shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Turn Therapeutics beats Lantern Pharma on 9 of the 12 factors compared between the two stocks.

How does Lantern Pharma compare to Precision BioSciences?

Lantern Pharma (NASDAQ:LTRN) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Precision BioSciences has a consensus price target of $32.25, indicating a potential upside of 294.25%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Lantern Pharma has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

Lantern Pharma has higher earnings, but lower revenue than Precision BioSciences. Lantern Pharma is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A
Precision BioSciences	$34.26M	6.16	-$45.72M	-$3.67	N/A

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by company insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Precision BioSciences had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Precision BioSciences and 0 mentions for Lantern Pharma. Precision BioSciences' average media sentiment score of 0.28 beat Lantern Pharma's score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantern Pharma	Neutral
Precision BioSciences	Neutral

Lantern Pharma has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -85.37% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-198.34%	-129.08%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Summary

Precision BioSciences beats Lantern Pharma on 10 of the 15 factors compared between the two stocks.

How does Lantern Pharma compare to Compugen?

Compugen (NASDAQ:CGEN) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Compugen has a net margin of 47.97% compared to Lantern Pharma's net margin of 0.00%. Compugen's return on equity of 47.72% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Lantern Pharma	N/A	-198.34%	-129.08%

12.2% of Compugen shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Compugen has a beta of 2.76, indicating that its stock price is 176% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market.

Compugen presently has a consensus price target of $5.00, suggesting a potential upside of 119.30%. Given Compugen's stronger consensus rating and higher probable upside, equities analysts clearly believe Compugen is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Compugen has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

In the previous week, Compugen had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 1 mentions for Compugen and 0 mentions for Lantern Pharma. Compugen's average media sentiment score of 0.75 beat Lantern Pharma's score of 0.00 indicating that Compugen is being referred to more favorably in the media.

Company	Overall Sentiment
Compugen	Positive
Lantern Pharma	Neutral

Summary

Compugen beats Lantern Pharma on 15 of the 16 factors compared between the two stocks.

How does Lantern Pharma compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Lantern Pharma is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

In the previous week, Nkarta's average media sentiment score of 0.00 equaled Lantern Pharma'saverage media sentiment score.

Company	Overall Sentiment
Nkarta	Neutral
Lantern Pharma	Neutral

80.5% of Nkarta shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 9.8% of Nkarta shares are held by insiders. Comparatively, 8.5% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nkarta's return on equity of -30.90% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Lantern Pharma	N/A	-198.34%	-129.08%

Nkarta presently has a consensus target price of $10.75, suggesting a potential upside of 233.85%. Given Nkarta's stronger consensus rating and higher probable upside, equities analysts clearly believe Nkarta is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nkarta has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market.

Summary

Nkarta beats Lantern Pharma on 10 of the 12 factors compared between the two stocks.

How does Lantern Pharma compare to Tonix Pharmaceuticals?

Lantern Pharma (NASDAQ:LTRN) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Lantern Pharma has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tonix Pharmaceuticals has a consensus price target of $24.00, suggesting a potential upside of 94.49%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than Lantern Pharma. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 0 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.00 beat Tonix Pharmaceuticals' score of -0.47 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Lantern Pharma	Neutral
Tonix Pharmaceuticals	Neutral

Lantern Pharma has higher earnings, but lower revenue than Tonix Pharmaceuticals. Lantern Pharma is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A
Tonix Pharmaceuticals	$13.11M	15.00	-$124.02M	-$14.36	N/A

Lantern Pharma has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-198.34%	-129.08%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

Summary

Tonix Pharmaceuticals beats Lantern Pharma on 9 of the 15 factors compared between the two stocks.

Get Lantern Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LTRN vs. The Competition

Export

Metric	Lantern Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$50.65M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.50%
P/E Ratio	-2.74	21.61	28.02	24.70
Price / Sales	N/A	325.90	532.59	98.61
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	6.84	8.66	10.96	6.46
Net Income	-$17.12M	$23.81M	$3.57B	$337.01M
7 Day Performance	2.85%	3.39%	2.12%	1.69%
1 Month Performance	10.58%	10.81%	5.25%	3.81%
1 Year Performance	24.84%	62.61%	33.29%	23.90%

Lantern Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LTRN Lantern Pharma	0.7108 of 5 stars	$3.97 flat	N/A	+24.8%	$50.65M	N/A	N/A	20	Gap Up
TTRX Turn Therapeutics	2.1321 of 5 stars	$7.30 +5.6%	$8.00 +9.6%	N/A	$205.84M	N/A	N/A	2	News Coverage Positive News Short Interest Decrease
DTIL Precision BioSciences	2.5335 of 5 stars	$7.86 -0.8%	$32.25 +310.3%	+87.0%	$204.35M	$34.26M	N/A	200	News Coverage
CGEN Compugen	3.799 of 5 stars	$2.14 -0.9%	$5.00 +133.6%	+28.1%	$204.24M	$72.76M	5.78	70	Gap Down
NKTX Nkarta	3.5979 of 5 stars	$2.83 -0.7%	$10.75 +279.9%	+83.5%	$203.90M	N/A	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LTRN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantern Pharma (LTRN) Competitors

LTRN vs. TTRX, DTIL, CGEN, NKTX, and TNXP

How does Lantern Pharma compare to Turn Therapeutics?

Summary

How does Lantern Pharma compare to Precision BioSciences?

Summary

How does Lantern Pharma compare to Compugen?

Summary

How does Lantern Pharma compare to Nkarta?

Summary

How does Lantern Pharma compare to Tonix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantern Pharma (LTRN) Competitors

LTRN vs. TTRX, DTIL, CGEN, NKTX, and TNXP

How does Lantern Pharma compare to Turn Therapeutics?

Which has better earnings and valuation, TTRX or LTRN?

Do analysts prefer TTRX or LTRN?

Does the media prefer TTRX or LTRN?

Is TTRX or LTRN more profitable?

Do institutionals and insiders have more ownership in TTRX or LTRN?

Summary

How does Lantern Pharma compare to Precision BioSciences?

Do analysts rate LTRN or DTIL?

Which has more risk and volatility, LTRN or DTIL?

Which has preferable earnings and valuation, LTRN or DTIL?

Do insiders and institutionals believe in LTRN or DTIL?

Does the media favor LTRN or DTIL?

Is LTRN or DTIL more profitable?

Summary

How does Lantern Pharma compare to Compugen?

Is CGEN or LTRN more profitable?

Do insiders & institutionals hold more shares of CGEN or LTRN?

Which has more risk & volatility, CGEN or LTRN?

Do analysts rate CGEN or LTRN?

Which has preferable earnings and valuation, CGEN or LTRN?

Does the media refer more to CGEN or LTRN?

Summary

How does Lantern Pharma compare to Nkarta?

Which has stronger valuation & earnings, NKTX or LTRN?

Does the media refer more to NKTX or LTRN?

Do institutionals and insiders hold more shares of NKTX or LTRN?

Is NKTX or LTRN more profitable?

Do analysts rate NKTX or LTRN?

Which has more risk & volatility, NKTX or LTRN?

Summary

How does Lantern Pharma compare to Tonix Pharmaceuticals?

Which has more risk and volatility, LTRN or TNXP?

Do insiders and institutionals hold more shares of LTRN or TNXP?

Do analysts recommend LTRN or TNXP?

Does the media prefer LTRN or TNXP?

Which has preferable valuation and earnings, LTRN or TNXP?

Is LTRN or TNXP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools